Pfizer (PFE) Raises Quarterly Dividend 5.9% to $0.36, 3.3% Yield; Authorizes New $10B Buyback

Pfizer (PFE) Enters Strategic Research Collaboration & License Agreement with Kineta Immuno-Oncology to Develop New Cancer Immunotherapies

December 17, 2018 8:08 AM EST

Pfizer Inc. (NYSE: PFE) today announced that it has entered into a strategic research collaboration with Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc. to develop RIG-I agonist immunotherapies for the treatment of cancer. The research collaboration and license agreement grants to Pfizer the exclusive rights to KIO's RIG-I screening platform and related compounds and technologies. The companies will collaborate to develop and test small molecule agonists that target RIG-I, an innate immunostimulatory pathway that can elicit immunogenic cell death (ICD) in tumors, providing both direct tumor cell killing and... More

Pfizer (PFE) Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV

December 14, 2018 10:29 AM EST

Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for ZIRABEV (bevacizumab), a potential biosimilar to Avastin (bevacizumab).1 ZIRABEV is a monoclonal antibody for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or... More

Pfizer (PFE) Commences Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) Candidate, PF-06482077

December 14, 2018 8:01 AM EST

Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older.

While the full extent of Prevenar 13 protection of adults is still being realized, we anticipate our 20vPnC vaccine candidate will be the next important step to help protect adults from a substantial invasive pneumococcal disease and pneumonia burden, including disease caused by serotypes not yet covered by any... More

Merck bolsters animal health unit with $2.4 billion Antelliq purchase

December 14, 2018 7:05 AM EST

By Tamara Mathias

(Reuters) - Merck and Co (NYSE: MRK) said on Friday it will buy privately held French company Antelliq Group, which makes digital identification products for livestock, for about 2.1 billion euros ($2.37 billion) to bolster its fast-growing animal health business.

The move affirms the drugmaker's commitment to the business, which Wall Street analysts have long seen value in separating just as rival drugmakers Eli Lilly and Co (NYSE:... More

BMO Capital Reiterates Market Perform on Pfizer (PFE) Following Investor Meetings

December 13, 2018 7:34 AM EST

BMO Capital analyst, Alex Arfaei, reiterated a Market Perform rating and $46.00 price target on Pfizer (NYSE: PFE) following recent investor meetings with management. Overall, management's commentary was in line with Arfaei's bullish views on most assets.

Management was very bullish about the... More